Looking at patient 5, suffering from PDTC, sorafenib was an effective drug at the beginning, but, in the further clinical course, an elevation of the tumor marker thyroglobuline (TG) was recorded, thus providing evidence of a tumor recurrence. Here, TG is linked to neoplasm.